
Opinion|Videos|December 23, 2024
Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion
Panelists discuss how chronic spontaneous urticaria involves autoantibody-mediated mast cell activation and degranulation, with BTK serving as a critical signaling molecule in both mast cells and B cells that produce pathogenic autoantibodies.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Please provide a brief overview of the pathophysiology of chronic spontaneous urticaria (CSU), including the role of Bruton Tyrosine Kinase (BTK).
- How would targeting BTK through inhibition be a strategy in the treatment of CSU?
- Briefly preview the two BTK inhibitors currently in development for CSU (remibrutinib and rilzabrutinib), including what phase of development each is in and what kind of data is currently published or expected.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
How Dermatology PAs Can Master Rapid Diagnostic Recognition
2
STAT6, ITK Inhibitors, IL-31, & IL-18 Headline Burgeoning Pipeline in Atopic Dermatitis, with David Rosmarin, MD
3
Emerging Evidence in Atopic Dermatitis Management, With Harrison Nguyen, MD, MBA, MPH
4
Managing FCS: LPL-Targeted Therapy, Drug Rationalization, and Atherosclerosis Risk
5






























































